PPT-meeting summary Autumn 2021 MEETINGS in Multiple Myeloma

IMW SOHO SOHO Italy Dr Claudio Cerchione MD PhD Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS Meldola Italy HIGHLIGHTS FROM LYMPHOMA amp MYELOMA CONNECT. What is smouldering myeloma? Smouldering myeloma (also known as asymptomatic myeloma) is a veryslow-growing type of myeloma. Myeloma, also known as multiple myeloma, is a type of bone marrow cancerari Dr. Andrew Chantry. Senior Clinical Lecturer and Honorary Consultant in . Haematology. University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust. UKMF Autumn Educational Day ‘The evolving management of multiple myeloma and related plasma cell disorders’. Our Dana-Farber Experience. Deirdre Foley & Matthew Murphy. Our . Dana-Farber Experience. Dr O Gorman (. MIRT . Mater Institute of Blood Cancer Research and Therapy) and Dr Anderson (Dana Farber Cancer Institute, Boston). Topics. Current Treatment Options for Relapsed/Refractory Multiple Myeloma. Topics. Relapsed/Refractory MM. Treatment Goals and Strategies. Relapsed/Refractory MM. Exposure to Stem Cell Toxic Agents Not An Issue for Most Patients . Ready for Prime Time?. DANA-FARBER . CANCER INSTITUTE. Nikhil C. Munshi, MD . Professor of Medicine . Harvard Medical School. Boston VA Healthcare System. Director . Basic and Correlative Sciences. Dana-Farber Cancer . NICE Guideline. Published Feb 2016. Adults with myeloma (and plasma cell leukaemia). Excluded:. Monoclonal . gammopathy. of uncertain significance (MGUS). Amyloidosis. Solitary . plasmacytomas. Included:. Study of . clinocopathological. profile and chromosomal abnormalities by FISH in newly diagnosed multiple myeloma. Investigator – Dr. . Sukanya. S K.. Guide: Dr. . Shivani. . Vignesh. .. Co-guide- Dr . We believe that there are a number of reasons for this including late & insufficient advertising, but also that it is harder to justify a single day meeting now, when many meetings are competing for attention. Smoldering Myeloma: To Treat or not to Treat Ruben Niesvizky MD Myeloma Center Myelomacenter.org run9001@med.cornell.edu CASE A 47-year-old man is diagnosed with smoldering multiple myeloma . He has Starr Morning Report Austin Akers, MD Internal Medicine PGY-3 Patient is a 59 year old previously fit and active male in remarkably good health for his age who has experienced a rapid overall physical decline over the last 2-3 months Pritesh Patel, MD. OVErview. Disease overview. How I approach initial treatment. Treatment considerations at relapse. ≈96,000. MM patients. How many people are affected by myeloma?. National Cancer Institute Survival Epidemiology and End Results Program SEER Cancer Statistics Review 1975-2012. Available at . Part I: Smoldering Multiple Myeloma . and . Induction Therapy for Patients with Newly Diagnosed Multiple Myeloma . Moderator: . Sagar. . Lonial. , MD. Panelists: . Jonathan Kaufman, MD and Ajay . Nooka. cyclin. and PI3k pathways. UKMF Spring meeting 2015. Kwee Yong, UCL Cancer Institute. Not one, but many myelomas. Dysregulation. of D-type . cyclin. in multiple myeloma. Early oncogenic events . dysregulate. H . Nèji. , H . Abid. , A . Mâalej. , S . Haddar. , R . Akrout. *, . M . Ezzeddine. *, S . Baklouti. *, . Z . Mnif. **, J . Mnif. Imaging department . Habib. . Bourguiba. Hospital, . *Rheumatology department .